Patent 11958902 was granted and assigned to Merck Sharp & Dohme Limited on April, 2024 by the United States Patent and Trademark Office.
The present invention relates to anti-TIGIT antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.